Stock of the Day

October 20, 2022

Aurora Cannabis (ACB)

$3.99
-$0.11 (-2.7%)
Market Cap: $262.22M

About Aurora Cannabis

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

Today's Trend

Aurora Cannabis Inc. (NASDAQ: ACB) is being supported by improving European operations and takeover speculation, although broader cannabis-sector weakness and uncertainty around U.S. reform remain risks. The stock has recently traded above its 50-day and 200-day moving averages, indicating stronger momentum than earlier in the year.

  • German production expansion: Aurora completed a multi-million-dollar expansion of its Leuna, Germany, EU-GMP facility. The project is expected to more than double annual flower output, increase domestic German supply and apply Aurora’s established cultivation practices and proprietary genetics. Greater European production capacity could support medical-cannabis revenue and reduce reliance on Canadian sales. Aurora Completes Major Expansion of European EU-GMP Manufacturing Facility
  • Raised takeover offer: Curaleaf Holdings has reportedly increased its hostile offer for Aurora to an implied US$5.00 per share and extended the tender deadline. The higher bid provides a potential valuation benchmark and could encourage further negotiations or a competing offer, though completion is not assured. Curaleaf Could Be Undervalued After Its Raised Aurora Bid
  • Reform and investor attention: Commentary continues to highlight renewed momentum around cannabis-policy reform as a possible catalyst for ACB and the broader sector. However, the articles provide no confirmed policy change, so the near-term benefit remains speculative. Can Aurora Cannabis Keep Rallying as Reform Momentum Resurfaces?
  • Short-interest data: A market update reported zero shares sold short as of October 9, implying no measurable days-to-cover. The figure may reflect a data or reporting anomaly, so it offers little reliable signal for ACB’s direction.
  • Sector weakness: Tilray’s weaker cannabis sales, despite record overall revenue, pressured cannabis-sector sentiment and coincided with declines in several peers, including Aurora. This reinforces concerns that cannabis growth remains uneven even as companies expand in Europe. Tilray Brands Sinks as Cannabis Sales Shrink
← Previous Stock of the DayNext Stock of the Day →

Recent News